Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.49 |
| ▸ | AR | P10275 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724025 | 0.85 | MAPT (0.63) | MAPTHTR2BALDH1A1KDM4ECYP19A1 | |
| Bromide SCHEMBL8881037 | 0.83 | MAPT (0.61) | MAPTHTR2BALDH1A1KDM4ECYP19A1 | |
| SCHEMBL4539676 | 0.81 | MAPT (0.69) | MAPTHTR2BALDH1A1KDM4EKMT2A | |
| SCHEMBL21357610 | 0.81 | MAPT (0.64) | MAPTHTR2BALDH1A1KDM4ECYP19A1 | |
| SCHEMBL6211632 | 0.81 | MAPT (0.64) | MAPTHTR2BALDH1A1KDM4ECYP19A1 | |
| SCHEMBL2225761 | 0.81 | MAPT (0.64) | MAPTHTR2BALDH1A1KDM4ECYP19A1 | |
| SCHEMBL10068466 | 0.81 | MAPT (0.64) | MAPTHTR2BALDH1A1KDM4ECYP19A1 | |
| SCHEMBL2089805 | 0.81 | MAPT (0.59) | MAPTHTR2BALDH1A1KDM4EKMT2A | |
| SCHEMBL2439363 | 0.81 | CYP19A1 (0.66) | MAPTALDH1A1KDM4ECYP19A1KMT2A | |
| SCHEMBL18002826 | 0.78 | MAPT (0.59) | MAPTHTR2BALDH1A1KDM4EAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831168-B1 | PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES. | VERTEX PHARMA (US) | 2014-07-02 | — | — | EP | disclosed |
| CN-102850324-A | Indole compounds | MICROBIA INC | 2013-01-02 | — | — | CN | disclosed |
| EP-1697348-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-12-28 | — | — | EP | disclosed |
| US-7696226-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2010-04-13 | — | — | US | disclosed |
| CN-101563337-A | Indole compounds | MICROBIA INC (US) | 2009-10-21 | — | — | CN | disclosed |
| EP-1697348-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
| WO-2005061487-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-07-07 | — | — | WO | disclosed |
| CN-1319092-A | Benzamide derivatives and their use as cytokine inhibitors | ASTRAZENECA AB (SE) | 2001-10-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | MAPT 2176/4885HTR2B 3973/4885ALDH1A1 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.